购物车
- 全部删除
- 您的购物车当前为空
Valbenazine (NBI-98854) 是一种高度选择性的囊泡单胺转运蛋白 2 (VMAT2) 抑制剂,Ki 为 110-190 nM,用于治疗迟发性运动障碍。
Valbenazine (NBI-98854) 是一种高度选择性的囊泡单胺转运蛋白 2 (VMAT2) 抑制剂,Ki 为 110-190 nM,用于治疗迟发性运动障碍。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 343 | 现货 | |
2 mg | ¥ 496 | 现货 | |
5 mg | ¥ 993 | 现货 | |
10 mg | ¥ 1,590 | 现货 | |
25 mg | ¥ 2,930 | 现货 | |
50 mg | ¥ 4,430 | 现货 | |
100 mg | ¥ 6,260 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 996 | 现货 |
产品描述 | Valbenazine (NBI-98854), a highly selective vesicular monoamine transporter 2(VMAT2) inhibitor, is approved for the treatment of tardive dyskinesia. |
体内活性 | Valbenazine 在接受长达48周治疗的成年TD患者中似乎具有良好的耐受性。除了长期疗效结果外,还表明Valbenazine可能适用于长期管理TD,无论患者的基础精神疾病诊断为何(SCHZ disorder或mood disorder)[1]。 |
动物实验 | The pooled long-term exposure (LTE) population included valbenazine-treated subjects from 3 studies: KINECT; KINECT 3; KINECT4. Safety assessments included adverse events (AEs), laboratory tests, vital signs, electrocardiograms (ECGs), and extrapyramidal symptom (EPS) scales. Psychiatric stability was monitored using the Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS) (SCHZ subgroup), as well as the Montgomery-?sberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) (mood subgroup). All data were analyzed descriptively[1]. |
别名 | NBI-98854 |
分子量 | 418.57 |
分子式 | C24H38N2O4 |
CAS No. | 1025504-45-3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 50 mg/mL (119.45 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.